# ImmunityBio (IBRX) — Earnings

IBRX · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/ibrx/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q4 2025 |
| Period end | Dec 31, 2025 |
| EPS actual | −$0.06 |
| EPS estimate | −$0.08 |
| EPS surprise | +21.57% |
| Revenue surprise | −0.20% |
| Revenue | $38.3M |
| Revenue estimate | $38.4M |
| Reported | Feb 23, 2026 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1326110/000132611026000025/ibrx-20260223.htm) |
| Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/067bf319-ec77-d884-7080-0312a8834e16.html) |

ImmunityBio reported Q4 2025 results on February 23, 2026. The company posted a loss of $0.06 per share, narrower than the expected loss of $0.08, a 21.57% beat. Revenue was $38.3 million, in line with the $38.4 million estimate. A year earlier, in Q4 2024, the loss was $0.09 per share and revenue $7.6 million, so revenue was about five times higher.

Every quarter in the table is a loss, but the losses have narrowed. The full-year loss shrank from $1.14 per share in 2023 to $0.63 in 2024. The deepest quarterly loss shown was $0.36 in Q4 2023, and Q4 2025 was the smallest. Revenue was below $0.5 million a quarter through 2023, then rose to $16.5 million in Q1 2025, $26.4 million in Q2 2025 and $38.3 million in Q4 2025. The record is patchy: there is no Q3 2025 row, and only single quarters appear for 2020 and 2022. ImmunityBio beat the EPS estimate in 5 of the 13 quarters shown, with one exactly in line.

The table holds no results after Q4 2025. In past years, first-quarter results came in May and third-quarter results in early to mid November.

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q4 2025 | Feb 23, 2026 | −$0.08 | −$0.06 | 21.57% | $38.4M | $38.3M |
| Q2 2025 | Aug 5, 2025 | −$0.11 | −$0.10 | 7.41% | $23.1M | $26.4M |
| Q1 2025 | May 12, 2025 | −$0.13 | −$0.15 | -17.19% | $16.0M | $16.5M |
| Q4 2024 | Mar 3, 2025 | −$0.20 | −$0.09 | 55.00% | $9.6M | $7.6M |
| Q3 2024 | Nov 12, 2024 | −$0.18 | −$0.14 | 21.35% | $2.9M | $6.1M |
| Q2 2024 | Aug 12, 2024 | −$0.16 | −$0.20 | -25.00% | $14.7M | $1.0M |
| Q1 2024 | May 9, 2024 | −$0.20 | −$0.20 | -2.56% | $62,500.00 | — |
| Q4 2023 | Mar 19, 2024 | −$0.18 | −$0.36 | -100.00% | $25,000.00 | $119,500.00 |
| Q3 2023 | Nov 9, 2023 | −$0.26 | −$0.19 | 25.49% | — | $82,000.00 |
| Q2 2023 | Aug 8, 2023 | −$0.24 | −$0.32 | -36.17% | — | $41,000.00 |
| Q1 2023 | May 11, 2023 | −$0.27 | −$0.27 | 0.00% | $25,000.00 | $400,000.00 |
| Q1 2022 | May 10, 2022 | −$0.22 | −$0.26 | -18.18% | $25,000.00 | $14,000.00 |
| Q1 2020 | May 11, 2020 | −$0.17 | −$0.19 | -11.76% | — | $21,000.00 |

## Frequently Asked Questions

### When did ImmunityBio (IBRX) last report earnings?

ImmunityBio last reported on Feb 23, 2026, covering fiscal Q4 2025.

### Did IBRX beat earnings estimates?

Yes. ImmunityBio reported EPS of −$0.06 for Q4 2025 against a −$0.08 estimate — a 21.57% beat.

### How much revenue did IBRX report last quarter?

ImmunityBio reported $38.3M in revenue for Q4 2025, against a consensus estimate of $38.4M.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).